文献速递类风湿关节炎

JAK抑制剂在类风湿关节炎治疗路径中的真实世界单中心应用

Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

联合组基线DAS28-CRP为5.62,3个月和6个月分别改善1.49和1.67,生物制剂初治者改善最显著,既往≥3种bDMARDs失败者DAS28-CRP改善仍>1.2,未记录意外安全事件。

要点

  • JAK抑制剂在真实世界RA患者中有效,包括多种bDMARDs难治者。
  • 生物制剂初治患者DAS28-CRP从5.16改善至2.14(6个月)。
  • 既往≥3种bDMARDs失败者DAS28-CRP改善仍>1.2。

核心结论

  • JAK抑制剂在真实世界RA人群中有效,包括对多种bDMARDs难治的亚组。

主要发现

  • 联合组基线DAS28-CRP为5.62(1.14),3和6个月分别改善1.49(1.44)和1.67(1.61)。
  • 生物制剂初治组6个月DAS28-CRP从5.16改善至2.14。
  • 既往≥3种bDMARDs失败者DAS28-CRP改善>1.2。
  • 3个月时24%患者达到至少低疾病活动度。

关键数值与推荐

  • 3个月时24%患者达到至少低疾病活动度。
  • 既往≥3种bDMARDs失败者DAS28-CRP改善>1.2。

临床怎么用

  • JAK抑制剂可用于真实世界RA患者,包括多种bDMARDs难治者。
  • 对IL-6阻断无效者,JAK抑制剂仍可能有效。

局限性

  • 单中心回顾性设计,样本量有限。
  • 未报告对照臂,疗效比较受限。
  • 随访仅至6个月,长期安全性数据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate real-world efficacy of approved JAK inhibitors (JAKi) tofacitinib and baricitinib in a large, single-centre cohort of RA patients across the treatment pathway, including those refractory to multiple biologic drugs. METHODS: All RA patients, treated with tofacitinib (from time of compassionate access scheme) or baricitinib since approval in 2017 had DAS28-CRP scores and components recorded at baseline, 3 and 6 months (with retrospective data for compassionate access scheme). Efficacy was evaluated in the total cohort, each treatment group, and subgroups of number of prior biologic classes failed. RESULTS: One hundred and fifteen patients were treated with a JAKi (tofacitinib 54, baricitinib 69, 8 both); 76.4% female; mean (s.d.) age 57.3 (14.3) years. On average patients had received three previous bDMARDs; 11 (9.6%) were bDMARD naïve. Combined group baseline DAS28-CRP (s.d.) 5.62(1.14) improved by 1.49(1.44) and 1.67(1.61) at 3 and 6 months, respectively, comparable in individual JAKi groups; with 24% in at least low disease activity at 3 months. The biggest improvement was observed in the biologic-naïve group (mean DAS28-CRP improved from 5.16-2.14 after 6 months); while those with prior exposure to minimum three bDMARD classes had DAS28-CRP improvement of >1.2. Five out of 8 patients treated with both JAKi sequentially responded. Twelve patients previously unresponsive to IL-6 blockade responded to JAKi. No unexpected safety events were recorded. Two cases of venous thromboembolism were observed. CONCLUSION: JAK inhibition is effective in a real-world population of RA patients, including in a subset of patients refractory to multiple previous bDMARDs.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Fitton J, Melville AR, Emery P, et al. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway. Rheumatology (Oxford). 2021. PMID: 33331938. doi:10.1093/rheumatology/keaa858

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。